← Therapy pipeline
Investigational · Obesity development

Bofanglutide (GZR18)

GZR18 · Gan & Lee Pharmaceuticals

GLP-1 injection with biweekly induction studies and a separate monthly maintenance study.

GLP-1
Other study areas
Type 2 diabetesSleep apnea
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorGan & Lee Pharmaceuticals
TargetsGLP-1
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

GRADUAL-1 · ChinaMean body-weight change from baselineBody weight decreased 18.54% · 52 weeks · Phase 3
Phase 3 · Injection · Sponsor-reported numerical results

Mean body-weight change from baseline · 52 weeks

Study focus: Weight management

Sponsor topline; Phase 3 China result, with a separate U.S. Phase 2 program.

Investigational regimen
18.5%
Placebo / comparator
1.1%

Adults with overweight or obesity in China · 48 mg every two weeks vs placebo · Trial N=640 · Modified intention-to-treat; sponsor topline. Results & methods ↗

Not a head-to-head comparison with other programs. Gastrointestinal events were generally mild to moderate; no new safety signal was reported.

U.S. Phase 2 · primary analysisMean body-weight change from baselineBody weight decreased 13.99% · 36 weeks · Phase 2
Phase 2 · Injection · Conference abstract

Mean body-weight change from baseline · 36 weeks

Study focus: Weight management without type 2 diabetes

Randomized U.S. Phase 2 trial: three bofanglutide regimens, placebo and an open-label tirzepatide arm.

Bofanglutide 48 mg every two weeks
13.99%
Placebo
0.84%

Adults with overweight or obesity without type 2 diabetes · 48 mg every two weeks · Trial N=325 · Full analysis set; primary treatment-regimen estimand. Results & methods ↗

U.S. Phase 2 · week-36 primary treatment-regimen estimates
RegimenMean weight reduction
Bofanglutide 24 mg every two weeks13.35%
Bofanglutide 36 mg every two weeks13.24%
Bofanglutide 48 mg every two weeks13.99%
Placebo0.84%
Additional results or analyses from this same study
  • Separate per-protocol analysis · same trialThe 48-mg group had 15.18% mean weight loss at week 36 in the earlier sponsor per-protocol report. This exploratory analysis differs from the full-analysis-set treatment-regimen estimates above. Follow-up source ↗

No dose-equivalence or superiority conclusion versus tirzepatide is established here. Gastrointestinal adverse events were the most common, generally mild to moderate. China GRADUAL-1 and monthly maintenance are separate studies.

GRADUAL-3 · monthly maintenanceMean body-weight change from maintenance baselineBody weight decreased 0.12% · 24-week maintenance period · Phase 3b
Phase 3b · Injection · Sponsor-reported Phase 3b topline

Mean body-weight change from maintenance baseline · 24-week maintenance period

Study focus: Weight-loss maintenance

Bofanglutide 48 mg monthly
0.12% decrease
Placebo monthly
8.52% increase

Eligible Chinese GRADUAL-1 completers after 52 weeks of biweekly bofanglutide · 24 or 48 mg once monthly after biweekly induction · N not included in this summary · Sponsor topline; analysis population and estimand not disclosed. Results & methods ↗

Same study · 24-week change from maintenance baseline
Monthly regimenWeight change
24 mg+0.41%
48 mg−0.12%
Placebo+8.52%
Additional results or analyses from this same study
  • 24 mg monthlyMean weight change was +0.41% versus +8.52% with placebo. Both active-dose comparisons had P<0.0001 in the sponsor topline.

Selected completers entered a separate maintenance period. Values start at maintenance baseline, not original induction baseline. Arm sizes, confidence intervals, estimand and numerical discontinuation rates were not disclosed; full publication is pending.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

Tolerability

Safety context

The sponsor described gastrointestinal events as generally mild to moderate, with no new safety signal in the reported studies.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionEvery two weeks; monthly maintenance studied
Phase 3China Phase 3 induction and Phase 3b monthly maintenance toplines reported
Milestone → next

Latest: Gan & Lee reported GRADUAL-3 monthly maintenance topline results on November 4, 2026, following 52 weeks of biweekly treatment in GRADUAL-1.

Next: Full GRADUAL-3 results and peer-reviewed reports; further regional development updates.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies2 records

Phase 3

GRADUAL-1 · China · NCT06728124

Weight management
Study: CompletedResults: Sponsor topline results shown above; no registry results postedStatus reviewed November 2026

China GRADUAL-1 completed March 26, 2026, with 640 actual participants (registry update posted November 12). The registry lists the primary weight endpoint at week 48; the separate sponsor topline reports 52-week results. Preserve those source-specific timepoints. No registry results are posted.

Phase 3b

GRADUAL-3 · monthly maintenance

Weight-loss maintenance
Study: Primary results reportedResults: Sponsor topline results shown aboveStatus reviewed November 2026

Randomized 24-week monthly maintenance after 52 weeks of biweekly bofanglutide in eligible GRADUAL-1 completers; 24 mg or 48 mg versus placebo. Separate from induction.

Phase 2 studies1 record

Phase 2

U.S. Phase 2 · NCT06737042

Weight management
Study: CompletedResults: Conference results shown above; no registry results postedStatus reviewed November 2026

325 participants randomized and treated: bofanglutide 24, 36 or 48 mg every two weeks, placebo, or open-label tirzepatide 15 mg weekly. Week-36 primary analysis uses the full analysis set and treatment-regimen estimand.